Free Trial
NASDAQ:MBRX

Moleculin Biotech Q2 2025 Earnings Report

Moleculin Biotech logo
$0.66 -0.03 (-4.21%)
Closing price 08/6/2025 04:00 PM Eastern
Extended Trading
$0.67 +0.01 (+2.18%)
As of 05:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moleculin Biotech EPS Results

Actual EPS
N/A
Consensus EPS
-$0.42
Beat/Miss
N/A
One Year Ago EPS
N/A

Moleculin Biotech Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Moleculin Biotech Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Wednesday, August 13, 2025
Conference Call Time
8:00AM ET

Conference Call Resources

Moleculin Biotech Earnings Headlines

A new rule goes live in July — and the banks are quietly crushing it
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
See More Moleculin Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Moleculin Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Moleculin Biotech and other key companies, straight to your email.

About Moleculin Biotech

Moleculin Biotech (NASDAQ:MBRX), a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

View Moleculin Biotech Profile

More Earnings Resources from MarketBeat